Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI
Information source: Uniformed Services University of the Health Sciences
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Traumatic Brain Injury
Intervention: methylphenidate (Drug); Placebo (Drug)
Phase: Phase 2
Status: Not yet recruiting
Sponsored by: Uniformed Services University of the Health Sciences Official(s) and/or principal investigator(s): Ramon R Diaz-Arrastia, MD, PhD, Study Director, Affiliation: Uniformed Services University / NINDS Eric Wassermann, MD, Principal Investigator, Affiliation: National Institute of Neurological Disorders and Stroke (NINDS)
Summary
Deficits in memory, attention, cognitive, and executive functions are the most common
disabilities after traumatic brain injury (TBI). Dopamine (DA) neurotransmission is
implicated in these neural functions and dopaminergic pathways are recognized to be
frequently disrupted after TBI. One of the most widely used DAergic drugs is methylphenidate
(Ritalin®). Methylphenidate increases synaptic DA levels by binding to presynaptic dopamine
transporters (DAT) and blocking re-uptake. PET with methylphenidate challenge to measure
tonic DA release provides valuable insight into the molecular basis of attention-deficit
hyperactivity disorder (ADHD) and addiction, as well as practical information regarding
likely effectiveness of therapy (1). The objectives of this study are to use PET imaging
with [11C]-raclopride, a D2/D3 receptor ligand, before and after administering
methylphenidate, to measure endogenous DA release in patients who are experiencing problems
with cognition, attention and executive function in the chronic stage after TBI. In
addition, we will use TMS to test short intracortical inhibition, a gamma-aminobutyric acid
receptor A (GABAA) - mediated phenomenon, which is under partial DA control, as a measure of
dopaminergic activity on and off methylphenidate.
Clinical Details
Official title: Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI
Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Relationship between tonic dopamine release (measured by displacement of [11C]-raclopride by oral methylphenidate) and change in processing speed between baseline and after methylphenidate treatment.
Secondary outcome: Relationship between D2/D3 receptor availability in ventral striatum and prefrontal cortex and neuropsychologic deficits.Relationship between tonic dopamine release in the ventral striatum and prefrontal cortex with neuropsychologic deficits after TBI. Relationship between D2/D3 receptor availability and functional connectivity of the prefrontal cortex with nodes of the default mode network. Relationship between TMS-induced short-interval cortical inhibition of M1 and tonic dopamine release. Test motivation and reward on and off methylphenidate in TBI patients.
Detailed description:
- Males and females (n=30), between the ages of 18 and 55 years in the chronic stage
after TBI who experience deficits in neuropsychological function from TBIs incurred 6
months after the injury, will be recruited from military treatment facilities or
civilian clinics when presenting for clinical management of TBI or post-concussive
symptoms.
- 1. Study participants will be evaluated using brain MRI, psychometric measures adapted
from the TBI Common Data Elements, attention tests and information about details of the
injury and experience of post-concussive symptoms will be recorded. Transcranial
magnetic stimulation (TMS) with placebo and with methylphenidate (60 mg by mouth)
challenge will be performed to predict a stimulant response.
- 2. Subjects will be studied with [11C]-raclopride PET in two imaging sessions. One
session will be after administration of placebo and the other after methylphenidate, 60
mg by mouth. Both placebo and methylphenidate will be given 60 minutes prior to
injection of [11C]-raclopride to allow for peak uptake of methylphenidate in the brain.
The binding potential of [11C]-raclopride relative to a non-displaceable reference
region (cerebellum), BPND, will be used as a measure of D2/D3 receptor availability.
The difference in BPND between methylphenidate and placebo (ΔBPND) is used to measure
of tonic DA release.
- 3. Subjects will then be treated with oral methylphenidate, using a forced titration up
to a dose of 30 mg given twice daily for 4 weeks. At that point, the neuropsychologic
tests are repeated.
- Outcome measures: The primary outcome is change in information processing speed during
neuropsychologic testing.
Eligibility
Minimum age: 18 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age 18 - 55 years, inclusive
- A history of having sustained a moderate or severe TBI > 6 months prior to
enrollment. Evidence will be any one of the following 3 criteria:
1. GCS 3 - 12 (GCS obtained in Emergency Room and noted in medical record)
2. Post-traumatic amnesia > 24 hours
3. TBI-related abnormality on neuroimaging (either CT or MRI).
- Persistent post-concussive symptoms, according to the DSM-IV Research Criteria for
Post-Concussional Disorder, including:
1. Difficulty in attention or memory.
2. One or more of the following symptoms, which started shortly after the trauma
and persist for at least three months:
1. Fatigability
2. Disordered sleep
3. Changes in personality
4. Apathy or lack of spontaneity
3. Symptoms in criteria (a) and (b) must have their onset after trauma, or there
was a significant worsening of pre-existing symptoms after trauma.
4. Disturbance from these symptoms causes significant impairment of social or
occupational functioning and represents a significant decline from previous
level of functioning.
- Ability to read, write, and speak English
- Ability to give informed consent.
Exclusion Criteria:
- Evidence of penetrating brain injury.
- Contraindication to methylphenidate therapy:
1. Known glaucoma (consistently raised intraocular pressure with or without
associated optic nerve damage)
2. Motor tics or a family history of Tourette's syndrome (diagnosed by presence of
both multiple motor and one or more vocal tics over the period of a year, with
no more than three consecutive tic-free months)
3. Known hypersensitivity to methylphenidate (hives, difficulty breathing, and
swelling of face, lips, tongue, or throat).
4. Known severe anxiety or restlessness which prevents from doing day to day
activities.
5. Known preexisting hypertension, heart failure, myocardial infarction, or
ventricular arrhythmia.
6. Known preexisting psychosis, bipolar illness.
7. History of seizures, or interictal epileptiform discharges (IEDs) on EEG in
absence of seizures.
8. Known peripheral vasculopathy, including Raynaud's phenomenon.
9. History of drug dependence or alcoholism.
10. Concomitant treatment with coumadin anticoagulants, anticonvulsants (e. g.,
phenobarbital, phenytoin, primidone), and tricyclic drugs (e. g., imipramine,
clomipramine, desipramine).
11. Concomitant therapy with monoamine oxidase inhibitors (such as Marplan
(isocarboxazid), Nardil (phenelzine), Emsam (selegiline), and Parnate
(tranylcypromine))
12. Concomitant treatment with blood pressure medication (both for high and low
blood pressure).
13. Pregnancy
14. Breastfeeding
- History or evidence of disabling pre-existing or co-existing disabling neurologic or
psychiatric disorders not related to TBI, such as:
1. Multiple sclerosis, pre- or co-existing
2. Stroke (other than stroke at the time of TBI)
3. Pre-existing disabling developmental disorder
4. Pre-existing epilepsy
5. Pre-existing major depressive disorder, aggressive behavior, hostility
6. Pre-existing schizophrenia
- Contraindication to MRI scanning
1. Ferromagnetic metal in the cranial cavity or eye, e. g., aneurysm clip, implanted
neural stimulator, cochlear implant, or ocular foreign body
2. Implanted cardiac pacemaker or auto-defibrillator or pump
3. Non-removable body piercing
4. Claustrophobia
5. Inability to lie supine for two hours
- Contraindication to TMS, such as metal in the cranial cavity or implanted electronic
hardware.
- Current participation in other interventional clinical trial
- Non-adherence to use of effective method of contraception for females of able to
become pregnant for time from enrollment to the study until 2 weeks after completion
of the study drug.
- Present history of alcohol and substance abuse disorder determined by DSM-IV
- Body mass index (BMI) > 30
Locations and Contacts
National Institutes of Health, Clinical Center., Bethesda, Maryland 20814, United States; Not yet recruiting Carol Moore, MA, CCRC, Phone: 301-295-6439, Email: carol.moore.ctr@usuhs.edu Ramon Diaz-Arrastia, MD, PhD, Principal Investigator Bogoslovsky Tanya, MD, Sub-Investigator Kimbra Kenney, MD, Sub-Investigator Carol Moore, MA, Sub-Investigator Bao-Xi Qu, MD, Sub-Investigator Yunhua Gong, MD, Sub-Investigator Franck Amyot, PhD, Sub-Investigator Nora Volkow, MD, Sub-Investigator Peter Herscovitch, MD, Sub-Investigator John Butman, MD, Sub-Investigator Dzung Pham, PhD, Sub-Investigator John Dsurney, PhD, Sub-Investigator Christian Shenouda, MD, Sub-Investigator Michael Tierney, MA, Sub-Investigator
Additional Information
Related publications: Volkow ND, Wang GJ, Tomasi D, Kollins SH, Wigal TL, Newcorn JH, Telang FW, Fowler JS, Logan J, Wong CT, Swanson JM. Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder. J Neurosci. 2012 Jan 18;32(3):841-9. doi: 10.1523/JNEUROSCI.4461-11.2012. Whyte J, Hart T, Vaccaro M, Grieb-Neff P, Risser A, Polansky M, Coslett HB. Effects of methylphenidate on attention deficits after traumatic brain injury: a multidimensional, randomized, controlled trial. Am J Phys Med Rehabil. 2004 Jun;83(6):401-20.
Starting date: September 2014
Last updated: May 27, 2014
|